Robert Kuhn: Sure. So George, consistent with requirements and what we’ve done in past segment realignment prior to our Q1 earnings, we’ll probably file an 8-K with the previous two years of 2022 and 2021 restated under the realignment as well as the quarterly splits for 2022. And that should give you the information you’ll need then not only for the upcoming 10-Qs, but then the 10-K at the end of the year.
George Staphos: Right. But I guess what I was saying, will you also give us beauty core growth, food core growth, etcetera, within the reclassified segments?
Robert Kuhn: Yes, and we’ll definitely give you color by market.
George Staphos: Okay. Last one, just on sustainability. Can you give us across the entity in total? And then within pharma specifically, what percentage of your products are recyclable, reasonable or composable, which I imagine is very little, but any metrics around that for the company and for pharma would be great. Thanks guys, good luck in the quarter and congrats on the performance this year to end the quarter — end of the year.
Stephan Tanda: Thanks. So I think the best place where you see this is our sustainability report. Clearly, the ratio is much higher in the consumer-facing products where it might be as much as 15%. In the pharma product, it’s just starting with consumer healthcare. While we’re talking about sustainability, you’ve seen in the growing recognition around everything sustainability, ESG. One is, of course, that is very important, the future proof of the company and future-proof the business. But I also want to highlight, it’s extremely important to our customers, and it’s extremely important to talent, whether I recruit for the board or senior positions or frontline positions, the first thing people say, Hey, I really love what you’re doing around sustainability. And therefore, we can compete above our weight class in recruiting. And clearly, for customers, it’s important that, in the end, drives preference when it comes to who to buy from.
George Staphos: Thanks Stephan.
Operator: Thank you George. We have no further questions on the line. I will now hand the floor back to Mr. Tanda for closing remarks.
Stephan Tanda: Great. Thank you all. Really appreciate everything the team has done. We ended with a solid quarter four despite the North American weakness in some of the consumer end users. We clearly are off to a strong year in quarter one, and we will overcome the consumer weakness here as well as well as the top pharma comps. As you know, the onetime costs, especially the ERP cost in injectable will be transitory, and we see good demand patterns in pharma and beauty continuing. Clearly, the first half will be strong and second half China should add to the momentum. I want to come back to the innovation pipeline. We showcased that in Congers for pharma, but also the beauty pipeline is building nicely as customers see our commitment with the innovation center and the new state-of-the-art facilities in Europe and in China.
As our major investments come online, our capital expenditures will come down somewhat — and I just talked about the sustainability recognition. So really looking ahead to a solid year. You may have also noticed that we are narrowing our range a bit. Hopefully, that some of this major uncertainty is behind us. And with that, we look forward to talking to you on the road.
Operator: Thank you. Ladies and gentlemen, this concludes today’s call. Thank you for joining. You may now disconnect your lines.
